578 related articles for article (PubMed ID: 26244699)
1. Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging Förster resonance energy transfer.
Sarabipour S; Del Piccolo N; Hristova K
Acc Chem Res; 2015 Aug; 48(8):2262-9. PubMed ID: 26244699
[TBL] [Abstract][Full Text] [Related]
2. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation.
Li E; You M; Hristova K
J Mol Biol; 2006 Feb; 356(3):600-12. PubMed ID: 16384584
[TBL] [Abstract][Full Text] [Related]
3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and forster resonance energy transfer suggest weak interactions between fibroblast growth factor receptor 3 (FGFR3) transmembrane domains in the absence of extracellular domains and ligands.
Li E; You M; Hristova K
Biochemistry; 2005 Jan; 44(1):352-60. PubMed ID: 15628877
[TBL] [Abstract][Full Text] [Related]
4. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
Del Piccolo N; Placone J; Hristova K
Biophys J; 2015 Jan; 108(2):272-8. PubMed ID: 25606676
[TBL] [Abstract][Full Text] [Related]
5. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
Sarabipour S; Hristova K
Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
[TBL] [Abstract][Full Text] [Related]
6. Studies of receptor tyrosine kinase transmembrane domain interactions: the EmEx-FRET method.
Merzlyakov M; Chen L; Hristova K
J Membr Biol; 2007 Feb; 215(2-3):93-103. PubMed ID: 17565424
[TBL] [Abstract][Full Text] [Related]
7. Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3.
Chen F; Sarabipour S; Hristova K
PLoS One; 2013; 8(2):e56521. PubMed ID: 23437153
[TBL] [Abstract][Full Text] [Related]
8. Transmembrane helix heterodimerization in lipid bilayers: probing the energetics behind autosomal dominant growth disorders.
Merzlyakov M; You M; Li E; Hristova K
J Mol Biol; 2006 Apr; 358(1):1-7. PubMed ID: 16500676
[TBL] [Abstract][Full Text] [Related]
9. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors.
Del Piccolo N; Sarabipour S; Hristova K
J Biol Chem; 2017 Jan; 292(4):1288-1301. PubMed ID: 27927983
[TBL] [Abstract][Full Text] [Related]
10. The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization.
Chen L; Placone J; Novicky L; Hristova K
Sci Signal; 2010 Nov; 3(150):ra86. PubMed ID: 21119106
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.
Meyers GA; Orlow SJ; Munro IR; Przylepa KA; Jabs EW
Nat Genet; 1995 Dec; 11(4):462-4. PubMed ID: 7493034
[TBL] [Abstract][Full Text] [Related]
12. Direct assessment of the effect of the Gly380Arg achondroplasia mutation on FGFR3 dimerization using quantitative imaging FRET.
Placone J; Hristova K
PLoS One; 2012; 7(10):e46678. PubMed ID: 23056398
[TBL] [Abstract][Full Text] [Related]
13. NMR-based approach to measure the free energy of transmembrane helix-helix interactions.
Mineev KS; Lesovoy DM; Usmanova DR; Goncharuk SA; Shulepko MA; Lyukmanova EN; Kirpichnikov MP; Bocharov EV; Arseniev AS
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):164-72. PubMed ID: 24036227
[TBL] [Abstract][Full Text] [Related]
14. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers.
You M; Spangler J; Li E; Han X; Ghosh P; Hristova K
Biochemistry; 2007 Oct; 46(39):11039-46. PubMed ID: 17845056
[TBL] [Abstract][Full Text] [Related]
15. A simple "proximity" correction for Förster resonance energy transfer efficiency determination in membranes using lifetime measurements.
Posokhov YO; Merzlyakov M; Hristova K; Ladokhin AS
Anal Biochem; 2008 Sep; 380(1):134-6. PubMed ID: 18559252
[TBL] [Abstract][Full Text] [Related]
16. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications.
Iwamoto T; You M; Li E; Spangler J; Tomich JM; Hristova K
Biochim Biophys Acta; 2005 Mar; 1668(2):240-7. PubMed ID: 15737335
[TBL] [Abstract][Full Text] [Related]
18. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
Bonaventure J; Horne WC; Baron R
FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 unliganded dimer stabilization by the juxtamembrane domain.
Sarabipour S; Hristova K
J Mol Biol; 2015 Apr; 427(8):1705-14. PubMed ID: 25688803
[TBL] [Abstract][Full Text] [Related]
20. Strong dimerization of wild-type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu mutant in mammalian plasma membranes.
Placone J; He L; Del Piccolo N; Hristova K
Biochim Biophys Acta; 2014 Sep; 1838(9):2326-30. PubMed ID: 24631664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
